Cite
HARVARD Citation
McQuilten, Z. et al. (2022). Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia. Leukemia & lymphoma. 63 (3), pp. 676-683. [Online].